These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28463521)

  • 41. [Clinical application of 18F-FDG PET/CT in the treatment of sarcomas].
    Borbély K; Németh Z; Kásler M
    Magy Onkol; 2014 Mar; 58(1):24-31. PubMed ID: 24712003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical PET in oncology: not only FDG.
    Nanni C; Rubello D; Al-Nahhas A; Fanti S
    Nucl Med Commun; 2006 Sep; 27(9):685-8. PubMed ID: 16894321
    [No Abstract]   [Full Text] [Related]  

  • 44. Is there a role for PET-CT and SPECT-CT in pediatric oncology?
    Biermann M; Schwarzlmüller T; Fasmer KE; Reitan BC; Johnsen B; Rosendahl K
    Acta Radiol; 2013 Nov; 54(9):1037-45. PubMed ID: 23319723
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Application of the PET for Radiation Therapy].
    Mitsumoto T; Tohyama N; Koyama K; Kodama T; Kotaka K; Hatano K
    Igaku Butsuri; 2015; 35(1):39-44. PubMed ID: 26753395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measuring response with FDG-PET: methodological aspects.
    Allen-Auerbach M; Weber WA
    Oncologist; 2009 Apr; 14(4):369-77. PubMed ID: 19357228
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential.
    Mercer JR
    J Pharm Pharm Sci; 2007; 10(2):180-202. PubMed ID: 17706177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Present status of PET images: clinical FDG PET in oncology].
    Inoue T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1999 Nov; 59(13):737-44. PubMed ID: 10614103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The potential role of non-FDG-PET in the management of head and neck cancer.
    Heuveling DA; de Bree R; van Dongen GA
    Oral Oncol; 2011 Jan; 47(1):2-7. PubMed ID: 21109481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluorodeoxyglucose-PET/Computed Tomography-Guided Biopsy.
    Cerci JJ; Tabacchi E; Bogoni M
    PET Clin; 2016 Jan; 11(1):57-64. PubMed ID: 26590444
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Evaluation of therapies in oncology by positron emission tomography: towards therapeutical personalization].
    Bonardel G; Vedrine L; Aupee O; Gontier E; Le Garlantezec P; Soret M; Foehrenbach H
    Bull Cancer; 2009 Feb; 96(2):213-26. PubMed ID: 19258228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PET and PET/CT in pediatric oncology.
    Jadvar H; Connolly LP; Fahey FH; Shulkin BL
    Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brain FDG PET and the diagnosis of dementia.
    Shivamurthy VK; Tahari AK; Marcus C; Subramaniam RM
    AJR Am J Roentgenol; 2015 Jan; 204(1):W76-85. PubMed ID: 25539279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PET Imaging of Metabolism, Perfusion, and Hypoxia: FDG and Beyond.
    Pantel AR; Bae SW; Li EJ; O'Brien SR; Manning HC
    Cancer J; 2024 May-Jun 01; 30(3):159-169. PubMed ID: 38753750
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PET imaging for assessing tumor response to therapy.
    Mankoff DA; Katz SI
    J Surg Oncol; 2018 Aug; 118(2):362-373. PubMed ID: 29938396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 18F-FDG imaging: pitfalls and artifacts.
    Abouzied MM; Crawford ES; Nabi HA
    J Nucl Med Technol; 2005 Sep; 33(3):145-55; quiz 162-3. PubMed ID: 16145222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Fluorodeoxyglucose F18(FDG)-probe guided biopsy].
    Hartemink KJ; Muller S; Smulders YM; Petrousjka van den Tol M; Comans EF
    Ned Tijdschr Geneeskd; 2010; 154():A1884. PubMed ID: 20858312
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Standardization and quantification in PET/CT imaging: tracers beyond FDG.
    Antunovic L; Rodari M; Rossi P; Chiti A
    PET Clin; 2014 Jul; 9(3):259-66. PubMed ID: 25030389
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strategies of assessing and quantifying radiation treatment metabolic tumor response using F18 FDG Positron Emission Tomography (PET).
    Fuss M
    Acta Oncol; 2010 Oct; 49(7):948-55. PubMed ID: 20831482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
    Powles T; Murray I; Brock C; Oliver T; Avril N
    Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.